Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Sell

Wall Street Data Solutions Rating

Neutral

B

Neurocrine Biosciences Inc (NBIX)

Biological Products, (no Disgnostic Substances)

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

12780 EL CAMINO REAL
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/23/1996

Market Cap

14,770,769,280

Shares Outstanding

98,250,000

Weighted SO

98,251,923

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

AMPH --.--%

COLL --.--%

IRWD --.--%

ANIP --.--%

DCPH --.--%

ALKS --.--%

AVDL --.--%

ITCI --.--%

DVAX --.--%

Beta

0.3670

Last Div

0.0000

Range

103.63-157.98

Chg

-1.4900

Avg Vol

799369

Mkt Cap

14770769280

Exch

NASDAQ

Country

US

Phone

858 617 7600

DCF Diff

-168.0868

DCF

314.7268

Div Yield

0.0000

P/S

6.9690

EV Multiple

26.4633

P/FV

5.8764

Div Yield %

0.0000

P/E

43.4700

PEG

5.5926

Payout

0.0000

Current Ratio

4.1902

Quick Ratio

4.0836

Cash Ratio

0.3506

DSO

80.6289

DIO

322.5052

Op Cycle

403.1341

DPO

813.4719

CCC

-410.3378

Gross Margin

0.9773

Op Margin

0.2570

Pretax Margin

0.2109

Net Margin

0.1600

Eff Tax Rate

0.2410

ROA

0.1026

ROE

0.1486

ROCE

0.1874

NI/EBT

0.7590

EBT/EBIT

0.8205

EBIT/Rev

0.2570

Debt Ratio

0.0882

D/E

0.1162

LT Debt/Cap

0.0926

Total Debt/Cap

0.1041

Int Coverage

165.0606

CF/Debt

1.8189

Equity Multi

1.3172

Rec Turnover

4.5269

Pay Turnover

0.4487

Inv Turnover

1.1318

FA Turnover

6.1793

Asset Turnover

0.6413

OCF/Share

5.2619

FCF/Share

4.9067

Cash/Share

10.3065

OCF/Sales

0.2502

FCF/OCF

0.9325

CF Coverage

1.8189

ST Coverage

14.9831

CapEx Coverage

14.8156

Div&CapEx Cov

14.8156

P/BV

5.8764

P/B

5.8764

P/S

6.9690

P/E

43.4700

P/FCF

29.8641

P/OCF

27.7998

P/CF

27.7998

PEG

5.5926

P/S

6.9690

EV Multiple

26.4633

P/FV

5.8764

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 02, 23:30 Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 GlobeNewswire Inc. May 28, 23:43 Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 The Motley Fool Feb 10, 23:18 Why Neurocrine Biosciences Stock Sank Today Benzinga Jan 23, 10:00 Unveiling 13 Analyst Insights On Neurocrine Biosciences Benzinga Dec 07, 11:00 Analyst Expectations for Neurocrine Biosciences's Future Benzinga Nov 10, 13:43 Why Is Neurocrine Biosciences Stock Trading Lower Today? MarketWatch Nov 10, 10:43 Lions Gate shares rise on surprise profit, Plug Power stock plunges on supply warning and more moving stocks MarketWatch Nov 10, 09:05 Lions Gate shares rise on surprise profit, Plug Power stock plunges on supply warning and more moving stocks Benzinga Nov 01, 13:00 Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know

Revenue Product Segmentation